The UCL Technology Fund invests in gene therapy company Freeline, which hopes to treat blood diseases such as haemophilia B.

Minnesota University co-leads a series A round in its spinout, which is working on gene editing therapies.

The WuXi PharmaTech-backed genomic medicine developer floated below its range, after raising $125m in venture capital.

Imperial Innovations has contributed to a series A round for small-molecule oncology treatment developer Storm Therapeutics, a Cambridge spinout.

EMBL Ventures backs Allecra Therapeutics' series B round that will support a phase 2 clinical trial for a therapy aimed at drug-resistant bacteria.

Pfizer and Merck's corporate venturing vehicles have contributed to small-molecule oncology treatment developer Storm Therapeutics' series A round.

The round, made up of an initial $34m and the conversion of $17m in bridge financing, included Medtronic and Cochlear and has a target size of $65m.

Media company Bonnier has taken part in a $5.9m round for fertility tracking app provider Natural Cycles through its Bonnier Media Growth investment subsidiary.

Gene-editing technology developer Crispr Therapeutics has secured $38m to increase a round backed by $65m from Bayer and Vertex Pharmaceuticals to $140m.